Published in Gynecol Oncol on May 24, 2006
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics (2009) 1.47
Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer (2009) 1.44
The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol (2011) 1.20
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer (2011) 1.19
Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Exp Cell Res (2007) 1.12
Filtering genes to improve sensitivity in oligonucleotide microarray data analysis. Nucleic Acids Res (2007) 1.12
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch (2007) 1.08
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology (2011) 1.01
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer (2008) 0.99
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96
Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study. Front Oncol (2014) 0.96
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. PLoS One (2013) 0.94
Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int J Mol Sci (2011) 0.91
Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci (2013) 0.89
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol (2009) 0.86
Characterization of adult α- and β-globin elevated by hydrogen peroxide in cervical cancer cells that play a cytoprotective role against oxidative insults. PLoS One (2013) 0.85
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer (2009) 0.85
Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med (2011) 0.84
Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis (2012) 0.83
Decreased expression and prognostic role of EHD2 in human breast carcinoma: correlation with E-cadherin. J Mol Histol (2015) 0.83
Identification of novel keloid biomarkers through profiling of tissue biopsies versus cell cultures in keloid margin specimens compared to adjacent normal skin. Eplasty (2010) 0.83
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer (2013) 0.82
Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther (2009) 0.82
Culture models to define key mediators of cancer matrix remodeling. Front Oncol (2014) 0.81
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. Int J Cancer (2015) 0.81
Effects of EHD2 interference on migration of esophageal squamous cell carcinoma. Med Oncol (2013) 0.81
Genome-wide profiling of pluripotent cells reveals a unique molecular signature of human embryonic germ cells. PLoS One (2012) 0.79
The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles. J Transl Med (2009) 0.77
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. J Transl Med (2013) 0.75
Claudin and ovarian cancer. J Turk Ger Gynecol Assoc (2010) 0.75
Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma. PLoS One (2017) 0.75
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol (2013) 0.75
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 4.79
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol (2003) 2.65
Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med (2003) 2.61
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol (2007) 2.48
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst (2006) 2.37
Massive pulmonary embolism. Circulation (2006) 2.27
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med (2005) 1.76
Drug utilisation profile in the Italian paediatric population. Eur J Pediatr (2008) 1.67
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer (2005) 1.60
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
The pathology of gastric cardia: a prospective, endoscopic, and morphologic study. Am J Surg Pathol (2007) 1.48
Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type. Int J Gynecol Pathol (2010) 1.47
HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol (2003) 1.43
Application of a latent variable model for a multicenter study on early effects due to mercury exposure. Neurotoxicology (2003) 1.42
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Multidimensional local false discovery rate for microarray studies. Bioinformatics (2005) 1.39
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer (2009) 1.38
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet (2008) 1.38
Estimation of false discovery proportion under general dependence. Bioinformatics (2006) 1.35
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci (2013) 1.32
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol (2005) 1.31
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res (2005) 1.28
Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res (2002) 1.27
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.25
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther (2013) 1.23
Identification of differentially expressed genes and false discovery rate in microarray studies. Curr Opin Lipidol (2007) 1.22
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol (2005) 1.20
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer (2003) 1.18
HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta (2011) 1.18
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol (2007) 1.18
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer (2010) 1.16
Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg (2007) 1.12
Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology (2005) 1.11
Clinical outcome after extended endovascular recanalization in Buerger's disease in 20 consecutive cases. Ann Vasc Surg (2012) 1.11
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol (2009) 1.10
Inappropriate use of anti-asthmatic drugs in the Italian paediatric population. Eur J Clin Pharmacol (2003) 1.10
Fetal DNA detection in maternal plasma throughout gestation. Hum Genet (2005) 1.09
Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis (2007) 1.09
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch (2007) 1.08
Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst (2010) 1.07
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer (2011) 1.06
Serum amyloid A: a novel biomarker for endometrial cancer. Cancer (2010) 1.05
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol (2013) 1.05
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev (2011) 1.04
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther (2010) 1.03
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res (2005) 1.02
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology (2011) 1.01
Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health (2013) 1.01
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol (2005) 1.00
Mental health and the global agenda. N Engl J Med (2013) 1.00
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol (2010) 1.00